Worth-Watching U.S. Stocks Alert: Anthera Pharmaceuticals Inc (NASDAQ:ANTH), Diamond Foods, Inc (NASDAQ:DMND), Calithera Biosciences Inc (NASDAQ:CALA), Finisar Corporation (NASDAQ:FNSR)

Following U.S. Stocks were among the “Top Gainers” during Friday’s trade: Anthera Pharmaceuticals Inc (NASDAQ:ANTH), Diamond Foods, Inc (NASDAQ:DMND), Calithera Biosciences Inc (NASDAQ:CALA), Finisar Corporation (NASDAQ:FNSR)

Their insights are depicted underneath:

Anthera Pharmaceuticals Inc (NASDAQ:ANTH)’s shares picked up 10.67%, and closed at $6.12, hitting new 52-week high of $6.36.

Anthera Pharmaceuticals, Inc. (ANTH), declared that Paul F. Truex, President and Chief Executive Officer, presented a corporate update on the progress of the Corporation’s development programs at the 35th Annual Cowen & Corporation Health Care Conference, on March 4, in Salon H on the 4th floor of the Boston Marriott Copley Place.

Anthera Pharmaceuticals is a biopharmaceutical corporation focused on developing and commercializing products to treat serious and life-threatening diseases, counting systemic lupus erythematosus, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.

Diamond Foods, Inc (NASDAQ:DMND), raised 10.41%, and closed at $30.34.

According to GLOBE NEWSWIRE, Diamond Foods, Inc. (DMND), stated financial results for its fiscal 2015 second quarter and six months ended January 31, 2015.

Second Quarter Fiscal 2015 Highlights:

Net sales were $229.7 million, up 4.1%
Snacks segment net sales were $120.4 million, up 3.2%
Nuts segment net sales were $109.2 million, up 5.2%
Gross margin was 26.6%, contrast to 25.4%
GAAP net revenue was $11.2 million and GAAP diluted earnings per share (“EPS”) was $0.35
Non-GAAP net revenue was $11.2 million and non-GAAP diluted EPS was $0.35, up 191.7%
Adjusted EBITDA was $33.8 million, up 18.4%.

Year-to-Date Fiscal 2015 Highlights:

Net sales were $476.3 million, up 4.6%
Snacks segment net sales were $237.0 million, up 3.3%
Nuts segment net sales were $239.3 million, up 5.9%
Gross margin was 25.3%, contrast to 25.0%
GAAP net revenue was $18.9 million and GAAP diluted earnings per share (“EPS”) was $0.59
Non-GAAP net revenue was $20.1 million and non-GAAP diluted EPS was $0.64, up 88.2%
Adjusted EBITDA was $64.5 million, up 11.9%.

Diamond Foods is an innovative packaged food corporation focused on building and energizing brands counting Kettle Brand(R) chips, Emerald(R) snack nuts, Pop Secret(R) popcorn, and Diamond of California(R) nuts. Diamond’s products are distributed in a wide range of stores where snacks and culinary nuts are sold.

Calithera Biosciences Inc (NASDAQ:CALA), enhanced 10.22%, and closed at $14.67.

According to GLOBE NEWSWIRE, Calithera Biosciences, Inc. (CALA), a clinical-stage pharmaceutical corporation focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, declared recently an exclusive global license contract with TransTech Pharma, a clinical stage pharmaceutical corporation, granting Calithera exclusive world-wide rights to research, develop and commercialize TransTech’s portfolio of hexokinase II inhibitors. Hexokinase II is the first and rate-limiting enzyme in the pathway that enables cancer cells to convert glucose to energy and building blocks that feed cancer cell growth. Under the terms of the contract, Calithera will obtain exclusive, worldwide rights to TransTech’s hexokinase II inhibitors for research, development and commercialization. TransTech will receive an upfront payment and will be eligible to receive future development and commercialization milestones in addition to royalties on sales of approved products.

“TransTech’s hexokinase II inhibitor program will further expand Calithera’s portfolio of pre-clinical programs and solidify our leadership in the area of tumor metabolism drug research and development as we are now able to target two essential nutrients that cancer cells rely on for growth and survival: glutamine and glucose,” said Susan M. Molineaux, CEO, Calithera Biosciences. “We believe we can apply our expertise to rapidly advance TransTech’s potent small-molecule hexokinase II inhibitors into the clinic to become our third potential first-in-class therapy for cancer patients.”

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical corporation focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.

Finisar Corporation (NASDAQ:FNSR), enhanced 9.35%, and closed at $22.23.

According to Marketwired, Finisar Corp. (FNSR), a global technology leader for subsystems and components for fiber optic communications, declared financial results for its third quarter of fiscal 2015, ended January 25, 2015.

Financial Statement Highlights for the Third Quarter of Fiscal 2015:

Proceeds raised to $306.3 million, up $9.3 million, or 3.1%, from $297.0 million in the preceding quarter.
Sales of products for datacom applications raised by $18.5 million, or 8.5%, contrast to the preceding quarter, primarily driven by the demand for 40 gigabit and 100 gigabit transceivers for datacom applications, in addition to transceivers for wireless applications.
Sales of products for telecom applications reduced by $9.2 million, or 11.3%, contrast to the preceding quarter, primarily due to the influence of one month of the annual telecom price reduction that typically takes effect on January 1 and the decrease in demand for transceivers for telecom applications driven by sluggish carrier capital expenditures.
GAAP gross margin reduced to 25.5% from 28.6% in the preceding quarter, primarily driven by a $5.7 million non-cash charge for the impairment of long-lived assets.
Non-GAAP gross margin reduced to 30.0% from 31.1% in the preceding quarter primarily due to the influence of one month of the annual telecom price reduction that typically takes effect on January 1 and the influence of substantial yield loss for a new optical engine product for supercomputing applications that we started to ramp in production during the quarter.
GAAP operating expenses reduced $17.6 million to $74.6 million from $92.2 million in the preceding quarter, primarily from expense reduction related to resolving patent infringement litigation that occurred in the preceding quarter.
Non-GAAP operating expenses reduced $2.2 million to $65.1 million from $67.3 million in the preceding quarter.
GAAP operating revenue raised $10.7 million, to $3.4 million or 1.1% of proceeds, contrast to an operating loss of $7.3 million or (2.4)% of proceeds in the preceding quarter, primarily as the result of higher proceeds and lower operating expenses.
Non-GAAP operating revenue raised $1.9 million to $26.9 million, or 8.8% of proceeds, contrast to $25.0 million, or 8.4% of proceeds, in the preceding quarter, primarily as the result of higher proceed and lower operating expenses.
Cash, cash equivalents and short term investments raised $11.4 million to $488.9 million at the end of the third quarter, contrast to $477.4 million at the end of the preceding quarter.

Finisar Corporation (FNSR) is a global technology leader for fiber optic subsystems and components that enable high-speed voice, video and data communications for telecommunications, networking, storage, wireless, and cable TV applications. For 25 years, Finisar has offered critical optics technologies to system manufacturers to meet the increasing demands for network bandwidth.